CLVLF (Clinuvel Pharmaceuticals) Inventories, Raw Materials & Components : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Inventories, Raw Materials & Components?

Clinuvel Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Dec. 2024 was $0.00 Mil.

Clinuvel Pharmaceuticals's quarterly raw materials increased from Dec. 2023 ($0.00 Mil) to Jun. 2024 ($0.38 Mil) but then declined from Jun. 2024 ($0.38 Mil) to Dec. 2024 ($0.00 Mil).

Clinuvel Pharmaceuticals's annual raw materials declined from Jun. 2022 ($0.37 Mil) to Jun. 2023 ($0.35 Mil) but then increased from Jun. 2023 ($0.35 Mil) to Jun. 2024 ($0.38 Mil).

Clinuvel Pharmaceuticals Inventories, Raw Materials & Components Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Inventories, Raw Materials & Components Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Inventories, Raw Materials & Components

Get a 7-Day Free Trial

0.18

0.39

0.37

0.35

0.38

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Inventories, Raw Materials & Components	Get a 7-Day Free Trial															-	0.35	-	0.38	-

Clinuvel Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

Clinuvel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Inventories, Raw Materials & Components

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.